Top

Published in:

01-06-2018 | Clinical Study

Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients

Authors: Adomas Bunevicius, Andrius Radziunas, Sarunas Tamasauskas, Arimantas Tamasauskas, Edwards R. Laws, Giorgio Iervasi, Robertas Bunevicius, Vytenis Deltuva

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

High sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) can be important prognostic indicators of brain tumor patients. We investigated the association of circulating IL-6 and hsCRP concentrations with discharge outcomes and survival of glioma and meningioma patients. One-hundred and sixty-three (115 women; median age 57 years) patients admitted for meningioma (n = 94), high-grade glioma (n = 48) and low-grade glioma (n = 21) surgery were enrolled in this prospective cohort study. Serum samples were collected within 24 h of admission. Discharge outcome was evaluated using the Glasgow Outcome Scale (unfavorable outcome = score from 1 to 3). Follow-up continued until November, 2016. Elevated IL-6 (≥ 2 pg/ml) and hsCRP (≥ 1 mg/l) concentrations were present in 25 and 35% of brain tumor patients, respectively. Elevated IL-6 concentrations were associated with unfavorable outcome at hospital discharge, adjusting for brain tumor histological diagnosis, patient age and gender (OR 2.39, 95% CI 0.97–5.91, p = 0.05). Elevated hsCRP concentrations were not associated with discharge outcome (p = 0.13). In multivariate Cox regression analyses adjusted for patient age, gender, extent of tumor resection and adjuvant treatment, elevated IL-6 concentration was associated with greater mortality risk in high-grade glioma patients (OR 2.623; 95% CI 1.129–5.597; p = 0.01), while elevated hsCRP concentration was associated with greater mortality risk in meningioma patients (OR 3.650; 95% CI 1.038–12.831; p = 0.04). Elevated IL-6 concentration is associated with greater unfavorable outcome risk in brain tumor patients and with greater mortality in high-grade glioma patients, while elevated hsCRP concentration is associated with greater mortality in meningioma patients.

Ostrom QT, Gittleman H, Xu J et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol 18(suppl_5):v1–v75. https://doi.org/10.1093/neuonc/now207 CrossRef

Wegman-Ostrosky T, Reynoso-Noverón N, Mejía-Pérez SI et al (2016) Clinical prognostic factors in adults with astrocytoma: Historic cohort. Clin Neurol Neurosurg 146:116–122. https://doi.org/10.1016/j.clineuro.2016.05.002 CrossRefPubMed

McGirt MJ, Chaichana KL, Gathinji M et al (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110(1):156–162. https://doi.org/10.3171/2008.4.17536 CrossRefPubMed

Mukherjee S, Thakur B, Corns R et al (2015) Resection of olfactory groove meningioma - a review of complications and prognostic factors. Br J Neurosurg 29(5):685–692. https://doi.org/10.3109/02688697.2015.1054348 CrossRefPubMed

van Alkemade H, de Leau M, Dieleman EMT et al (2012) Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol 14(5):658–666. https://doi.org/10.1093/neuonc/nos013 CrossRefPubMedPubMedCentral

Christofides A, Kosmopoulos M, Piperi C (2015) Pathophysiological mechanisms regulated by cytokines in gliomas. Cytokine 71(2):377–384. https://doi.org/10.1016/j.cyto.2014.09.008 CrossRefPubMed

Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B (2017) Immune microenvironment of gliomas. Lab Investig 97(5):498–518. https://doi.org/10.1038/labinvest.2017.19 CrossRefPubMed

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813(5):878–888. https://doi.org/10.1016/j.bbamcr.2011.01.034 CrossRefPubMed

Chang C-Y, Li M-C, Liao S-L, Huang Y-L, Shen C-C, Pan H-C (2005) Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 12(8):930–933. https://doi.org/10.1016/j.jocn.2004.11.017 CrossRefPubMed

10.

Todo T, Adams EF, Rafferty B, Fahlbusch R, Dingermann T, Werner H (1994) Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth. J Neurosurg 81(3):394–401. https://doi.org/10.3171/jns.1994.81.3.0394 CrossRefPubMed

11.

Jones TH, Justice SK, Timperley WR, Royds JA (1997) Effects of interleukin-1 and dexamethasone on interleukin-6 production and growth in human meningiomas. J Pathol 183(4):460–468CrossRefPubMed

12.

Park K-J, Kang S-H, Chae Y-S et al (2010) Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg 112(1):73–80. https://doi.org/10.3171/2009.4.JNS09158 CrossRefPubMed

13.

Baumann H, Gauldie J (1994) The acute phase response. Immunol Today 15(2):74–80. https://doi.org/10.1016/0167-5699(94)90137-6 CrossRefPubMed

14.

Aulin J, Siegbahn A, Hijazi Z et al (2015) Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J 170(6):1151–1160. https://doi.org/10.1016/j.ahj.2015.09.018 CrossRefPubMed

15.

Hedman A, Larsson PT, Alam M, Wallen NH, Nordlander R, Samad BA. CRP (2007) IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? Int J Cardiol 120(1):108–114. https://doi.org/10.1016/j.ijcard.2006.09.004 CrossRefPubMed

16.

Kersten C, Louhimo J, Ålgars A et al (2013) Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol 52(8):1691–1698. https://doi.org/10.3109/0284186X.2013.835494 CrossRefPubMed

17.

Licastro F, Hrelia S, Porcellini E et al (2016) Peripheral Inflammatory markers and antioxidant response during the post-acute and chronic phase after severe traumatic brain injury. Front Neurol 7:189. https://doi.org/10.3389/fneur.2016.00189 CrossRefPubMedPubMedCentral

18.

Pusch G, Debrabant B, Molnar T et al (2015) Early dynamics of P-selectin and interleukin 6 predicts outcomes in ischemic stroke. J Stroke Cerebrovasc Dis 24(8):1938–1947. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.05.005 CrossRefPubMed

19.

Patgiri D, Pathak MS, Sharma P, Kutum T, Mattack N (2014) Serum hsCRP: a novel marker for prediction of cerebrovascular accidents (stroke). J Clin Diagn Res 8(12):CC08-11. https://doi.org/10.7860/JCDR/2014/10386.5302 PubMed

20.

Strojnik T, Smigoc T, Lah TT (2014) Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. Anticancer Res 34(1):339–347PubMed

21.

Reynés G, Vila V, Martín M et al (2011) Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 102(1):35–41. https://doi.org/10.1007/s11060-010-0290-x CrossRefPubMed

22.

Jennett B, Bond M (1975) Assessment of outcome after severe brain damage. Lancet (London, England) 1(7905):480–484. http://www.ncbi.nlm.nih.gov/pubmed/46957. Accessed 4 Sept 2017

23.

Bunevicius A, Deltuva V, Tamasauskas S, Tamasauskas A, Laws ER, Bunevicius R (2013) Low triiodothyronine syndrome as a predictor of poor outcomes in patients undergoing brain tumor surgery: a pilot study: clinical article. J Neurosurg 118(6):1279–1287. https://doi.org/10.3171/2013.1.JNS121696 CrossRefPubMed

24.

Iłzecka J, Iłzecki M (2006) APRIL is increased in serum of patients with brain glioblastoma multiforme. Eur Cytokine Netw 17(4):276–280PubMed

25.

Doroudchi M, Pishe ZG, Malekzadeh M, Golmoghaddam H, Taghipour M, Ghaderi A (2013) Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev 14(9):5225–5230CrossRefPubMed

26.

Kataki A, Skandami V, Memos N et al (2014) Similar immunity profiles in patients with meningioma and glioma tumors despite differences in the apoptosis and necrosis of circulating lymphocyte and monocyte populations. J Neurosurg Sci 58(1):9–15PubMed

27.

Demirci U, Yaman M, Buyukberber S et al (2012) Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. Int Immunopharmacol 14(4):546–549. https://doi.org/10.1016/j.intimp.2012.08.007 CrossRefPubMed

28.

Kumar R, Kamdar D, Madden L et al (2006) Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep 15(6):1513–1516PubMed

29.

Vignes JR, Sesay M, Rezajooi K, Gimbert E, Liguoro D (2008) Peritumoral edema and prognosis in intracranial meningioma surgery. J Clin Neurosci 15(7):764–768. https://doi.org/10.1016/j.jocn.2007.06.001 CrossRefPubMed

30.

Schoenegger K, Oberndorfer S, Wuschitz B et al (2009) Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 16(7):874–878. https://doi.org/10.1111/j.1468-1331.2009.02613.x CrossRefPubMed

31.

Shan Y, He X, Song W, Han D, Niu J, Wang J (2015) Role of IL-6 in the invasiveness and prognosis of glioma. Int J Clin Exp Med 8(6):9114–9120PubMedPubMedCentral

32.

Tchirkov A, Khalil T, Chautard E et al (2007) Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 96(3):474–476. https://doi.org/10.1038/sj.bjc.6603586 CrossRefPubMedPubMedCentral

33.

Wang H, Lathia JD, Wu Q et al (2009) Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27(10):2393–2404. https://doi.org/10.1002/stem.188 CrossRefPubMedPubMedCentral

34.

Kuo H-K, Yen C-J, Chang C-H, Kuo C-K, Chen J-H, Sorond F (2005) Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 4(6):371–380. https://doi.org/10.1016/S1474-4422(05)70099-5 CrossRefPubMed

35.

Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375(9709):132–140. https://doi.org/10.1016/S0140-6736(09)61717-7 CrossRef

36.

Bunevicius A, Kazlauskas H, Raskauskiene N et al (2015) Role of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and inteleukin-6 in predicting a poor outcome after a stroke. Neuroimmunomodulation 22(6):365–372. https://doi.org/10.1159/000381218 CrossRefPubMed

37.

Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA (2010) Association of C-reactive protein with cognitive impairment. Arch Neurol 67(1):87–92. https://doi.org/10.1001/archneurol.2009.308 CrossRefPubMedPubMedCentral

38.

Bunevicius A, Deltuva VP, Tamasauskas A (2017) Association of pre-operative depressive and anxiety symptoms with five-year survival of glioma and meningioma patients: a prospective cohort study. Oncotarget 8(34):57543–57551. https://doi.org/10.18632/oncotarget.15743 CrossRefPubMedPubMedCentral

Title: Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients
Authors: Adomas Bunevicius
Andrius Radziunas
Sarunas Tamasauskas
Arimantas Tamasauskas
Edwards R. Laws
Giorgio Iervasi
Robertas Bunevicius
Vytenis Deltuva
Publication date: 01-06-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2803-y

At a glance: The STEP trials

Springer Medicine

Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Allergic conditions and risk of glioma and meningioma in the CERENAT case-control study

CyberKnife robotic radiosurgery in the multimodal management of acromegaly patients with invasive macroadenoma: a single center’s experience

Diagnosis of non-osseous spinal metastatic disease: the role of PET/CT and PET/MRI

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity

Information needs and requirements in patients with brain tumours and their relatives

Risk of post-operative venous thromboembolism in patients with meningioma